Phenotyping of drug-metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes

Pharmacogenetics

Volumn 10, Issue 3, 2000, Pages 187-216

  Streetman, Daniel S ^a,c   Bertino Jr , Joseph S ^a,b   Nafziger, Anne N ^a,b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b BASSETT HEALTHCARE   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Cytochrome P450; Drug metabolism; Phenotyping; Probes

Indexed keywords

ALFENTANIL; CAFFEINE; CHLORZOXAZONE; CYCLOSPORIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; CYTOCHROME P450 ISOENZYME; DAPSONE; DEBRISOQUINE; DEXTROMETHORPHAN; DIMETHYLNITROSAMINE DEMETHYLASE; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; HYDROCORTISONE; LIDOCAINE; LOSARTAN; MEPHENYTOIN; METOPROLOL; MIDAZOLAM; NIFEDIPINE; OMEPRAZOLE; PHENACETIN O DEETHYLASE; PHENYTOIN; PROGUANIL; SPARTEINE; THEOPHYLLINE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

BREATH ANALYSIS; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG URINE LEVEL; DRUG USE; ENZYME ACTIVITY; HUMAN; PHENOTYPE; PRIORITY JOURNAL; RELIABILITY; REVIEW; SIDE EFFECT; TECHNIQUE;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0034007388     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200004000-00001     Document Type: Review

References (230)

1. Al-Hadidi HF, Irshaid YM, Rawashdeh NM. Metoprolol α-hydroxylation is a poor probe for debrisoquine oxidation (CYP2D6) polymorphism in Jordanians. Eur J Clin Pharmacol 1994; 47:311-314.
2. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther 1981; 30:653-661.
3. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA. et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995; 57:662-669.
4. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 1989; 46:521-527.
5. Bartkowski RR, Goldberg ME, Larijani GE, Boerner T. Inhibition of alfentanil metabolism by erythromycin. Clin Pharmacol Ther 1989; 46:99-102.
6. Bathum L, Andersen-Ranberg K, Boldsen J, Brosen K, Jeune B. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity. Eur J Clin Pharmacol 1998; 54:427-430.
7. Bendriss A, Bechtel Y, Paintaud G, Bendriss EK, Joanne C, Bresson-Hadni S, et al. Stability of debrisoquine (CYP2D6) phenotype in liver transplant patients. Ther Drug Monit 1995; 17:113-119.
8. Bertilsson L, Dengler HJ, Eichelbaum M, Schulz HU. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol 1980; 17:153-155.
9. Bienvenue T, Rey E, Pons G, d'Athis P, Olive G. A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans. Int J Clin Pharmacol Ther Toxicol 1991; 29:441-445.
10. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME. In-vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 1994; 37:413-420.
11. Bonati M, Latini R, Galletti F, Young JF, Tognoni G, Garattini S. Caffeine disposition after oral doses. Clin Pharmacol Ther 1982; 32:98-106.
12. Bozkurt A, Basci NE, Isimer A, Sayal A, Kayaalp SO. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a crossover study. Eur J Drug Metab Pharmacokinet 1996; 21:309-314.
13. Brockmöller J, Rost KL, Gross D, Schenkel A, Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R-and S-mephenytoin and comparison with the intron4/ exon5 G - A-splice site mutation. Pharmacogenetics 1995; 5:80-88.
14. Brosen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 1986; 30:679-684.
15. Brosen K, Skjelbo E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993; 36:105-108.
16. PA (P-450IA2), the phenacetin O-decthylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989; 86:7696-7700.
17. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2:116-127.
18. Cakaloglu Y, Tredger JM, Devlin J, Williams R. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. Hepatology 1994; 20:309-316.
19. Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987a: 42:157-165.
20. Campbell ME, Grant DM, Inaba T, Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 1987b; 15:237-249.
21. Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther 1996; 60:295-307.
22. Carriere V, Goasduff T, Ratanasavanh D, Morel F, Gautier JC, Guillouzo A, et al. Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol 1993; 6:852-857.
23. Cederberg C, Andersson T, Skanberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol 1989; 24 (Suppl 166):33-40.
24. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5:358-363.
25. Chauvin M, Bonnet F, Montembault C, Levron JC, Viars P. The influence of hepatic blood flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient. Anesth Analg 1986; 65:999-1003.
26. Chen L-S, Yasumori T, Yamazoe Y, Kato R. Hepatic microsomal tolbutamide hydroxylation in Japanese: in vitro evidence for rapid and slow metabolizers. Pharmacogenetics 1993; 3:77-85.
27. Daly AK, Salh BS, Bilton D, Allen J, Knight AD, Webb AK, et al. Deficient nifedipine oxidation: a rare inherited trait associated with cystic fibrosis kindreds. Pharmacogenetics 1992; 2:19-24.
28. Dayer P, Leemann T, Striberni R. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity. Clin Pharmacol Ther 1989; 45:34-40.
29. Denaro CP, Benowitz NL. Caffeine metabolism: disposition in liver disease and hepatic-function testing. In: Watson RR, editor. Drug and alcohol abuse reviews, vol. 2: liver pathology and alcohol. New Jersey: The Humana Press; 1991, pp. 513-539.
30. Denaro CP, Brown CR, Wilson M, Jacob P III, Benowitz NL. Dose-dependency of caffeine metabolism with repeated dosing. Clin Pharmacol Ther 1990; 48:277-85.
31. Denaro CP, Wilson M, Jacob P III, Benowitz NL. Validation of urine caffeine metabolite ratios with the use of stable isotope-labeled caffeine clearance. Clin Pharmacol Ther 1996; 59:284-296.
32. Dreisbach AW, Ferencz N, Hopkins NE, Fuentes MG, Rege AB, George WJ, et al. Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity. Clin Pharmacol Ther 1995; 58:498-505.
33. Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM, Tyndale RF. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 1998; 8:325-333.
34. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16:183-187.
35. Eichelbaum M, Bertilsson L, Sawe J, Zekorn C. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 1982; 31:184-186.
36. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J Jr, Crom WR. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989; 45:568-573.
37. Evans WE, Relling MV. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics 1991; 1:143-148.
38. Fabre I, Fabre G, Maurel P, Bertault-Peres P, Cano JP. Metabolism of cyclosporin A. III. Interaction of the macrolide antibiotic, erythromycin, using rabbit hepatocytes and microsomal fractions. Drug Metab Dispos 1988; 16:296-301.
39. Fleming CM, Kaisary A, Wilkinson GR, Smith P, Branch RA. The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. Pharmacogenetics 1992a; 2:128-134.
40. Fleming CM, Branch RA, Wilkinson GR, Guengerich FP. Human liver microsomal N-hydroxylation of dapsone by cytochrome P4503A4. Mol Pharmacol 1992b; 41:975-980.
41. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and saliva. Pharmacogenetics 1994; 4:109-116.
42. Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in-vivo versus in-vitro correlations. Pharmacogenetics 1996; 6:159-176.
43. Funck-Brentano C, Thomas G, Jacqz-Aigrain E, Poirier JM, Simon T, Bereziat G, et al. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther 1992; 263:780-786.
44. Funck-Brentano C, Becquemont L, Leneveu A, Roux A, Jaillon P, Beaune P. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in-vivo results from the in-vitro experiments. J Pharmacol Exp Ther 1997; 280:730-738.
45. Ged C, Rouillon JM. Pichard L, Combalbert J, Bressot N, Bories P, et al. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989; 28:373-387.
46. Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 1994; 47:1503-1508.
47. Glazko AJ, Peterson FE, Chang T, Dill WA, Smith TC, Buchanan RA. Phenytoin metabolism in subjects with long and short plasma half-lives. Ther Drug Monit 1982; 4:281-292.
48. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994a; 33:1743-1752.
49. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994b; 4:285-299.
50. Gorski JC, Hall FD, Jones DR, Vanderbranden M, Wrighton SA. Midazolam metabolism to 4-OH midazolam and 1′OH-midazolam by human cytochrome P450 3A. Clin Pharmacol Ther 1993; 53:188.
51. Gorski JC, Jones DR, Wrighton SA, Hall SD. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 1997; 27:243-256.
52. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998a; 64:133-143.
53. Gorski JC, Haehner BD, Cutler D, Affrime MB, Hall SD. Lack of correlation between intravenous midazolam and oral dextromethorphan CYP3A phenotypes. Clin Pharmacol Ther 1998b; 63:150.
54. Gotzkowsky SK, Kashuba ADM, Hall W, Kulawy RW, Beck DJ, Rocci ML Jr, et al. Poor correlation between 24-hour urinary 6β-hydroxycortisol: Cortisol molar ratios (CMR) and plasma midazolam clearance (MDZ CL) as measures of hepatic CYP3A activity. Clin Pharmacol Ther 1999; 65:167.
55. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983; 33:591-602.
56. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2:73-77.
57. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986; 261:5051-5060.
58. Guengerich FP. Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. Am J Clin Nutr 1995; 61 (Suppl):651S-658S.
59. Guengerich FP, Shimada T. Activation of procarcinogens by human cytochrome P450 enzymes. Mut Res 1998; 400:201-213.
60. Guitton J, Buronfosse T, Desage M, Lepape A, Brazier J-L, Beaune P. Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol 1997; 53:1613-1619.
61. Ha HR, Chen J, Freiburghaus AU, Follath F. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995; 39:321-326.
62. Hartter S, Kohler D, Fuchs K, Sieghart W, Hiemke C, Dextrorphan N-demethylation, a marker reaction for CYP3A activity? Eur J Clin Pharmacol 1997; 52 (Suppl):A133.
63. 14C-midazolam in humans following oral dosing. Arzneimittel-Forschung 1981; 31:2220-2223.
64. Henthorn TK, Avram MJ, Krejcie TC. Alfentanil clearance is independent of the polymorphic debrisoquin hydroxylase. Anesthesiology 1989; 71:635-639.
65. Horai Y, Taga J, Ishizaki T, Ishikawa K. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. Br J Clin Pharmacol 1990; 29:111-115.
66. Horsmans Y, Kanyinda JM, Desager JP. Relationship between mephenytoin, phenytoin and tolbutamide hydroxylations in healthy African subjects. Pharmacol Toxicol 1996; 78:86-88.
67. Hoskins JM, Shenfield GM, Gross AS. Relationship between proguanil metabolic ratio and CVP2C19 genotype in a Caucasian population. Br J Clin Pharmacol 1998; 46:499-504.
68. Hou ZY, Pickle LW, Meyer PS, Woosley RL. Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 1991; 49:410-419.
69. Hu OYP, Tang HS, Lane HY, Chang WH, Hu TM. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J Pharmacol Exp Ther 1998; 285:955-960.
70. Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, Watlington CO, et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 1992; 51:18-23.
71. Inaba T, Otton SV, Kalow W. Debrisoquine hydroxylation capacity: problems of assessment in two populations. Clin Pharmacol Ther 1981; 29:218-223.
72. Inaba T. Phenytoin: pharmacogenetic polymorphism of 4′-hydroxylation. Pharmacol Ther 1990; 46:341-347.
73. Iyun AO, Lennard MS, Tucker GT, Woods HF. Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 1986; 40:387-394.
74. Jackson PR, Tucker GT, Lennard MS, Woods HF. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol 1986; 22:541-550.
75. Jackson PR, Tucker GT, Woods HF. Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism - hypothesis testing. Br J Clin Pharmacol 1989; 28:655-662.
76. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993; 3:197-204.
77. Johnson JA, Burlew BS. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos 1996; 24:350-355.
78. Jones DR, Gorski JC, Haehner BD, O'Mara EM Jr., Hall SD. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin Pharmacol Ther 1996; 60:374-384.
79. Kadlubar FF, Talaska G, Butler MA, Teitel CH, Masseng JP, Lang NP. Determination of carcinogenic arylamine N-oxidation phenotype in human by analysis of caffeine urinary metabolites. Prog Clin Biol Res 1990; 340B:107-114.
80. Kalow W, Tang B. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991; 49:44-48.
81. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53:503-514.
82. Kashuba AD, Bertino JS Jr, Kearns GL, Leader JS, James AW, Gotschall R, et al. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther 1998; 63:540-551.
83. Kashuba ADM, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Gaedigk A, et al. Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity. Pharmacogenetics 1999; 9:453-462.
84. Kassai A, Toth G, Eichelbaum M, Klotz U. No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. Clin Pharmacokinet 1988; 15:319-325.
85. Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Clin Pharmacol Ther 1998; 63:151.
86. Kazierad DJ, Martin DE, Blum RA, Tenero DM, Ilson B, Boike SC, et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997; 62:417-425.
87. Kevorkian JP, Michel C, Hofmann U, Jacqz-Aigrain E, Kroemer HK, Peraldi MN, et al. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. Clin Pharmacol Ther 1996; 59:583-592.
88. Khanderia U, Pandit SK. Use of midazolam hydrochloride in anesthesia. Clin Pharm 1987; 6:533-547.
89. Kharasch ED, Thummel KE. Human alfentanil metabolism by cytochrome P450 3A3/4. An explanation for the interindividual variability in alfentanil clearance? Anesth Analg 1993a; 76:1033-1039.
90. Kharasch ED, Thummell KE, Mhyre J, Lillibridge JH. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clin Pharmacol Ther 1993b; 53:643-650.
91. Kharasch ED, Russell M, Garton K, Lentz G, Bowdle TA, Cox K. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology 1997; 87:26-35.
92. Kim RB, O'Shea D, Wilkinson GR. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995; 57:645-655.
93. Kim JS, Kashuba ADM, Nafziger AN, Rocci ML, Kulawy RW, Beck DJ, et al. Optimal plasma sampling to predict AUC of the CYP3A probe midazolam (MID). Clin Pharmacol Ther 1999; 65:185.
94. Kimura M, Ieiri I, Wada Y, Mamiya K, Urae A, Iomori E, et al. Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease, and length of therapy. Br J Clin Pharmacol 1999; 47:115-119.
95. Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, et al. Absence of correlations among three putative in-vivo probes of human cytochrome P-4503A4 activity in young healthy men. Clin Pharmacol Ther 1993; 54:621-629.
96. Kleinbloesem CH, Brummelen P van, Faber H, Danhof M, Vermeulen NPE, Breimer DD. Variability in nifedipine pharmacokinetics: a new oxidation polymorphism in man. Biochem Pharmacol 1984; 33:3721-3724.
97. 2 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clin Pharmacol Ther 1982; 32:261-269.
98. Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK. Urinary excretion of 6β-hydroxycortisol as an in-vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther 1998; 63:617-622.
99. Krivoruk Y, Kinirons MT, Wood AJJ, Wood M. Alfentanil disposition in-vivo is mediated by CYP3A4 in humans. Anesthesiology 1994; 81:A380.
100. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36:89-96.
101. Kupfer A, Desmond P, Patwardhan R, Schenker S, Branch RA. Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin Pharmacol Ther 1984a; 35:33-39.
102. Kupfer A, Schmid B, Preisig R, Pfaff G. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 1984b; 2:517-518.
103. Kupfer A, Schmid B, Pfaff G. Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 1986; 16:421-433.
104. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED. Catalytic role of cytochrome P450 3A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 1995; 23:490-496.
105. Lamba JK, Dhiman RK, Kohli KK. Genetic polymorphism of the hepatic cytochrome P450 2C19 in North Indian subjects. Clin Pharmacol Ther 1998; 63:422-427.
106. Lane EA, Parashos I. Drug pharmacokinetics and the carbon dioxide breath test. Drug Pharmacokinet Biopharmaceut 1986; 14:29-49.
107. Larrey D, Babany G, Tinel M, Freneaux E, Amouyal G, Habersetzer F, et al. Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients. Br J Clin Pharmacol 1989; 28:297-304.
108. Lasker JM, Wester MR, Aramsombatdee E, Raucy JL. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles of microsomal tolbutamide, S-mephenytoin and omeprazole hydroxylations. Arch Biochem Biophys 1998; 353:16-28.
109. Lee C. Urinary 6β-hydroxycortisol in humans: analysis, biological variations and reference ranges. Clin Biochem 1995; 28:49-54.
110. Leeder JS, Gaedigk A, Gupta G, Simon S, Henne K, Allen K, et al. Determinants of warfarin S:R ratio in orthopedic surgery (OS) patients. Clin Pharmacol Ther 1999; 65:194.
111. Lennard MS, Tucker GT, Woods HF, Silas JH, Iyun AO. Stereo-selective metabolism of metoprolol in Caucasians and Nigerians - relationship to debrisoquine oxidation phenotype. Br J Clin Pharmacol 1989; 27:613-616.
112. Lindley C, Decker J, McCune J, Kashuba A, Meadowcroft A, Hall W, et al. Dextromethorphan (DM) and cortisol metabolic ratios: correlates of CYP3A4 activity. Clin Pharmacol Ther 1998; 63:217.
113. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58:641-649.
114. Lown K, Kolars J, Turgeon K, Merion R, Wrighton SA, Watkins PB. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin Pharmacol Ther 1992; 51:229-238.
115. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22:947-955.
116. Lown KS, Thummell KE, Benedict PE, Shen DD, Turgeon DK, Berent S, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995; 57:16-24.
117. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2:584-586.
118. Masimirembwa C, Hasler J, Bertilssons L, Johansson I, Ekberg O. Ingelman-Sundberg M. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 1996; 51:117-122.
119. May DG, Arns PA, Richards WO, Porter J, Ryder D, Fleming CM, et al. The disposition of dapsone in cirrhosis. Clin Pharmacol Ther 1992; 51:689-700.
120. May DG, Porter J, Wilkinson GR, Branch RA. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 1994; 55:492-500.
121. McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo M-W, et al. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin Pharmacol Ther 1999; 65:348-352.
122. McCune J, Lindley C, Sawyer W, Williamson K, Kashuba A, Pieper J. Comparison of 24-hour and morning 6βOH cortisol: cortisol ratio in men; women on oral contraceptives and women not on oral contraceptives. Clin Pharmacol Ther 1998; 63:219.
123. Meadowcraft AM, Williamson KM, Patterson JH, Hinderliter AL, Pieper JA. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39:418-424.
124. Meuldermans W, Van Peer A, Hendrickx J, Woestenborghs R, Lauwers W, Heykants J, et al. Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology 1988; 69:527-534.
125. Meyer UA, Skoda RC, Zanger UM, Heim M, Broly F. The genetic polymorphism of debrisoquine/sparteine metabolism - molecular mechanisms. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon; 1992. pp. 609-623.
126. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18:84-112.
127. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45:525-538.
128. Mishin VM, Rosman AS, Basu P, Kessova I, Oneta CM, Lieber CS. Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans. Am J Gastroenterol 1998; 93:2154-2161.
129. Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 1995; 58:556-566.
130. Mortimer O, Lindstrom B, Laurell H, Bergman U, Rane A. Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. Br J Clin Pharmacol 1989; 27:223-227.
131. Ndanusa BU, Mustapha A, Abdu-Aguye I. The effect of single doses of rifampicin on the pharmacokinetics of oral nifedipine. J Pharm Biomed Anal 1997; 15:1571-1575.
132. Nordmark A, Lundgren S, Cnattingius S, Rane A. Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. Br J Clin Pharmacol 1999; 47:397-402.
133. Notarianni LJ, Oliver SE, Dobrocky P, Bennett PN, Silverman BW. Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity. Br J Clin Pharmacol 1995; 39:65-69.
134. Oellerich M, Burdelski M, Schulz M, Schmidt FW, Ringe B, Lamesch P, et al. Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function. J Clin Chem Clin Biochem 1987; 25:845-853.
135. Ohmori S, Nakasa H, Asanome K, Kurose Y, Ishii I, Hosokawa M, et al. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim Biophys Acta 1998; 1380:297-304.
136. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53:298-305.
137. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ. Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 1995; 5:143-150.
138. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994; 56:359-367.
139. Osikowska-Evers B, Dayer P, Meyer UA, Robertz GM, Eichelbaum M. Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers. Clin Pharmacol Ther 1987; 41:320-325.
140. O'Sullivan TA, Wang JP, Unadkat JD, Al-Habet SMH, Trager WF, Smith AL, et al. Disposition of drugs in cystic fibrosis. V. Invivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. Clin Pharmacol Ther 1993; 54:323-328.
141. Partovian C, Jacqz-Aigrain E, Keundjian A, Jaillon P, Funck-Brentano C. Comparison of chloroguanide and mephenytoin for the in-vivo assessment of genetically determined CYP2C19 activity in humans. Clin Pharmacol Ther 1995; 58:257-263.
142. Pentikainen PJ, Valisalmi L, Himberg JJ, Crevoisier C. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 1989; 29:272-277.
143. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990; 3:566-573.
144. 2 breath test. Pediatr Res 1988; 23:632-636.
145. Puchetti V, Faccini GB, Micciolo R, Ghimenton F, Bertrand C, Zatti N. Dextromethorphan test for evaluation of congenital predisposition to lung cancer. Chest 1994; 105:449-453.
146. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39:151-159.
147. Rasmussen BB, Brosen K. Theophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humans. Br J Clin Pharmacol 1997; 43:253-258.
148. Regardh CG. Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol 1986; 21 (Suppl 118):99-104.
149. Reichel C, Nacke A, Sudhop T, Wienkoop G, Luers C, Hahn C, et al. The low-dose monoethylglycinexylidide test: assessment of liver function with fewer side effects. Hepatology 1997; 25:1323-1327.
150. Reichel C, Skodra T, Nacke A, Spengler U, Sauerbruch T. The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. Br J Clin Pharmacol 1998; 46:535-539.
151. Relling MV, Ayers D, Heideman RL. Mephenytoin phenotyping: lack of haematologic effect and timing of urine collections. Pharmacogenetics 1991; 1:42-49.
152. Relling MV, Lin J, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992; 52:643-658.
153. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29:413-580.
154. Renner E, Wielholtz H, Huguenin P, Arnaud MJ, Preisig R. Caffeine: a model compound for measuring liver function. Hepatology 1984; 4:38-46.
155. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5:54-59.
156. Robson RA, Miners JO, Matthews AP, Stupans I, Meller D, McManus ME, et al. Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies. Biochem Pharmacol 1988; 37:1651-1659.
157. Rodrigues AD, Kukulka MJ, Surber BW, Thomas SB, Uchic JT, Rotert GA, et al. Measurement of liver microsomal cytochrome p450 (CYP2D6) activity using [O-methyl-14C]dextromethorphan. Anal Biochem 1994; 219:309-320.
158. Romkes-Sparks M, Mnuskin A, Chern H-D, Persad R, Fleming C. Sibley GNA et al. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in-vivo debrisoquine hydroxylase activity. Carcinogenesis 1994; 15:1955-1961.
159. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55:402-411.
160. Rost KL, Brockmoller J, Esdorn F, Roots I. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J Hepatol 1995; 23:268-277.
161. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996; 6:121-149.
162. Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT. Metaanalysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 1998; 8:227-238.
163. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
164. Saenger P. 6β-hydroxycortisol in random urine samples as an indicator of enzyme induction. Clin Pharmacol Ther 1983; 34:818-821.
165. Sanz EJ, Villen T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989; 45:495-499.
166. Sarkar MA, Hunt C, Guzelian PS, Karnes HT. Characterisation of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos 1992; 20:31-37.
167. Sarkar MA, Jackson B. Theophylline N-demethylations as probes for P4501A1 and P4501A2. Drug Metab Dispos 1994; 22:827-834.
168. Schadel M, Wu D, Otton SV, Kalow W, Sellers EM. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol 1995; 15:263-269.
169. Schellens JHM, Soons PA, Breimer DD. Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 1988; 37:2507-2510.
170. Schellens JHM, van der Wart JHF, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a 'cocktail' study design. J Pharmacol Exp Ther 1989; 249:638-645.
171. Schellens JH, Ghabrial H, van der Wart HH, Bakker EN, Wilkinson GR, Breimer DD. Differential effects of quinidine on the disposition of nifedipine, sparteine and mephenytoin in humans. Clin Pharmacol Ther 1991; 50:520-528.
172. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985; 38:618-624.
173. Schmid BJ, Perry HE, Idle JR. Determination of nifedipine and its three principal metabolites in plasma and urine by automated electron-capture capillary gas chromatography. J Chromatogr 1988; 425:107-119.
174. Schmider J, Greenblatt DJ, Fogelman SM, Von Moltke LL, Shader RI. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos 1997; 18:227-240.
175. Setiabudy R, Chiba K, Kusaka M, Ishizaki T. Caution in the use of a 100 mg dose of racemic mephenytoin for phenotyping southeastern Oriental subjects. Br J Clin Pharmacol 1992; 33:665-666.
176. Simooya OO, Njunju E, Rostami Hodjegan A, Lennard MS, Tucker GT. Debrisoquine and metoprolol oxidation in Zambians: a population study. Pharmacogenetics 1993; 3:205-208.
177. Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51:288-295.
178. Sinues B, Saenz MA, Lanuza J, Bernal ML, Fanlo A, Juste JL, et al. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Cancer Epidemiol Biomarkers Prev 1999; 8:159-166.
179. Sloan TP, Lancaster R, Shah RR, Idle JR, Smith RL. Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol 1983; 15:443-450.
180. Smith MT, Eadie MJ. O'Rourke Brophy T. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 1981; 19:271-278.
181. Sommers DK, Moncrieff J, Avenant J. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Hum Toxicol 1989; 8:365-368.
182. Somogyi AA, Reinhard HA, Bochner F. Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. Br J Clin Pharmacol 1996; 41:175-179.
183. Soons PA, Mulders TM, Uchida E, Schoemaker HC, Cohen AF, Breimer DD. Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokinetics. Eur J Clin Pharmacol 1993; 44:163-169.
184. Spina E, Gitto C, Avenoso A, Campo GM, Caputti AP, Perucca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997; 51:395-398.
185. Stearns RA, Chakravarty PK, Chen R, Chiu SHL. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995; 23:207-215.
186. Streetman DS, Ellis RE, Nafziger AN, Leeder JS, Gaedigk A. Gotschall R, et al. Dose-dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping. Clin Pharmacol Ther 1999; 66:535-541.
187. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6:429-439.
188. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6:341-349.
189. Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998; 8:365-373.
190. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T. Interaction with p-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 1998; 358:289-294.
191. Tang BK, Zhou Y, Kadar D, Kalow W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic measurements. Pharmacogenetics 1994; 4:117-124.
192. Tassaneeyakul W, Birkett DJ, Pass MC, Miners JO. Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo. Br J Clin Pharmacol 1996; 42:774-778.
193. Thummel KE, Shen DD, Bacchi CE, McVicar JP, Marsh CL, Perkins JD, et al. Induction of human hepatic P4503A3/4 by phenytoin. Hepatology 1992; 16:160A.
194. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994a; 271:557-566.
195. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994b; 271:549-556.
196. Thummel KE, Wilkinson GR. In-vitro and in-vivo drug interactions involving human CYP3A. Ann Rev Pharmacol Toxicol 1998; 38:389-430.
197. Tija JF, Colbert J, Back DJ. Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 1996; 276:912-917.
198. Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR. Studies of flurbiprofen 4′-hydroxylation. Biochem Pharmacol 1996; 52:1305-1309.
199. Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, Martin DE. Morning spot and 24-hour urinary 6β-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J Clin Pharmacol 1999; 39:487-494.
200. Transon C, Lecoeur S, Leemann T, Beaune P, Dayer P. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. Eur J Clin Pharmacol 1996; 51:79-85.
201. Tucker GT, Rostami-Hodjegan A, Jackson PR. Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues. Xenobiotica 1998; 28:1255-1273.
202. Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 1992; 52:471-478.
203. Turgeon DK, Leichtman AB, Lown KS, Normolle DP, Deeb GM, Merion RM, et al. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther 1994; 56:253-260.
204. Tybring G, Bottger Y, Widen J, Bertilsson L. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 1997; 62:129-137.
205. Veronese ME, Miners JO, Randies D, Gregov D, Birkett DJ. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 1990; 47:403-411.
206. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991; 175:1112-1118.
207. Veronese ME, Miners JO, Rees DLP, Birkett DJ. Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. Pharmacogenetics 1993; 3:86-93.
208. Vessell ES, Seaton TD, A-Rahim YI. Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in-vivo probe. Pharmacogenetics 1995; 5:53-57.
209. Vinks A, Inaba T, Otton SV, Kalow W. Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther 1982; 31:23-29.
210. Wagner D. CYP3A4 and the erythromycin breath test. Clin Pharmacol Ther 1998; 64:129.
211. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996; 31:47-64.
212. Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994; 73:658-661.
213. Wanwimolruk S, Pratt EL, Denton JR, Chalcroft SCW, Barron PA, Broughton JR. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population. Pharmacogenetics 1995a; 5:193-198.
214. Wanwimolruk S, Thou MR, Woods DJ. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population. Br J Clin Pharmacol 1995b; 40:166-169.
215. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1991; 31:689-692.
216. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4:171-184.
217. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989; 83:688-697.
218. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhes JJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 1990; 48:120-129.
219. Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, et al. Comparisons of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992; 52:265-273.
220. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36:773-780.
221. Wedlund PJ, Sweetman BJ, Wilkinson GR, Branch RA. Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos 1987; 15:277-279.
222. Williamson KM, Patterson JH, McQueen RH, Adams KF. Pieper JA. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1998; 63:316-323.
223. Woolhouse NM, Eichelbaum M, Oates NS, Idle JR, Smith RL. Dissociation of co-regulatory control of debrisoquin/phenformin and SP oxidation in Ghanaians. Clin Pharmacol Ther 1985; 37:512-521.
224. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38:207-213.
225. Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its cys- and leu- variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 1998; 56:243-251.
226. Yun CH, Wood M, Wood AJJ, Guengerich FP. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. Anesthesiology 1992; 77:467-474.
227. Yun CH, Lee HS, Lee E, Rho JK, Jeong HG, Guengerich FP. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos 1995; 23:285-289.
228. Xhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ. Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1991: 31:350-352.
229. Zhiri A, Wellman-Bednawska M, Siest G. Elisa of 6β-hydroxycortisol in human urine: diurnal variations and effects of antiepileptic therapy. Clin Chimica Acta 1986; 157:267-276.
230. Zimmermann T, Schlenk R, Pfaff G, Lach P, Wildfeuer A. Prediction of phenotype for dextromethorphan O-demethylation by using polymerase chain reaction in healthy volunteers. Arzneimittelforschung 1995; 45:41-43.